Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults With HIV-1: Week 48 Subgroup Analyses of the Phase 3 ISLEND-1 Trial

Conference Reports for NATAP

HIV Glasgow 2026
8-11 November


Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults With HIV-1: Week 48 Subgroup Analyses of the Phase 3 ISLEND-1 Trial

	Glasgow 2026 Nov 8-11